UCB has announced new three-year data for BIMZELX (bimekizumab) in moderate to severe hidradenitis suppurativa (HS), showing sustained disease control and symptom resolution across the most stringent clinical endpoints.
Bimekizumab is the first approved treatment to selectively inhibit interleukin 17A and 17F. It continues to be well tolerated, with no new safety signals observed over three years.
Among patients with HS, HiSCR75, HiSCR90 and HiSCR100 responses seen at one year were sustained and improved to three years in 81.2%, 64.3% and 50.1% of patients, respectively. Quality of life improvements were also maintained, with 38.1% reporting no impact of skin disease.
Patients achieving IHS4-100 at year one sustained complete resolution of inflammatory lesions through to year two in 64.3% of cases. Earlier treatment was associated with better outcomes, particularly at higher efficacy thresholds.
At Week 96, patients with shorter disease duration (<2.38 years) achieved IHS4-100 in 46.1% of cases, compared to 22.8% in those with longer disease duration (≥10.74 years). Bimekizumab also reduced draining tunnels and skin pain over two years.
John Ingram, Professor of Dermatology, Cardiff University, said: “These data for bimekizumab – including HiSCR100 and IHS4-100 – showed disease control can be maintained long-term. Importantly, the resolution of inflammatory lesions highlights the potential to prevent long-term structural damage commonly associated with this disease.”
Donatello Crocetta, Chief Medical Officer, UCB, said: “The three-year data on bimekizumab presented at EADV demonstrated deep and sustained responses across stringent efficacy endpoints, as well as long-term improvements in health-related quality of life.”
The data will be presented at the European Academy of Dermatology and Venereology Congress in Paris, alongside other UCB research in inflammatory skin and joint diseases.
